AIMS/HYPOTHESIS: Knowledge of the factors which simultaneously contribute to insulin-resistance-related inflammation may contribute to early therapeutic targeting. IL-18 has recently been described as one of the factors which, in addition to insulin resistance, may also contribute to atherosclerosis. However, the source of IL-18 is not well characterised. MATERIALS AND METHODS: We aimed to study body composition (bioelectric impedance), glucose tolerance (OGTT) and insulin sensitivity (minimal model method) in relation to serum IL-18 (ELISA) concentration in 144 otherwise healthy men aged 51.9+/-12.5 years. RESULTS: In contrast to previous observations in women, circulating IL-18 was not significantly associated with BMI (r=0.12, p=0.1) or WHR (r=0.08, p=0.3). IL-18 was also not associated with absolute or percent fat mass (bioelectric impedance, p>0.20) but, interestingly, it was significantly linked to fat-free mass (p=0.03). Serum IL-18 increased with each quartile of fat-free mass, corresponding to values of < or = 64.2; >64.2 to < or = 71.6; >71.6 to < or = 80.9; and > or = 80.9 kg (ANOVA, p<0.0001). IL-18 was more closely associated with postload glucose during an OGTT (p=0.04) rather than with fasting glucose (p=0.1). HbA1c (p=0.03), HDL-cholesterol (p=0.04) and serum triglycerides (p=0.03) and parameters of systemic inflammation (C-reactive protein, p=0.02) were also significantly associated with circulating IL-18. Insulin sensitivity (minimal model analysis) was linked to circulating IL-18 (p=0.01). In a multiple linear regression analysis this relationship remained significant after controlling for BMI, age and glucose tolerance status. In another model, both fat-free mass and insulin sensitivity contributed to 10% of IL-18 variance. CONCLUSIONS/ INTERPRETATION: Fat mass does not seem to influence circulating IL-18, as initially proposed. In contrast, the fat-free mass compartment (a well-known confounder in the evaluation of insulin sensitivity) may significantly contribute to the relationship between IL-18 and insulin action.
AIMS/HYPOTHESIS: Knowledge of the factors which simultaneously contribute to insulin-resistance-related inflammation may contribute to early therapeutic targeting. IL-18 has recently been described as one of the factors which, in addition to insulin resistance, may also contribute to atherosclerosis. However, the source of IL-18 is not well characterised. MATERIALS AND METHODS: We aimed to study body composition (bioelectric impedance), glucose tolerance (OGTT) and insulin sensitivity (minimal model method) in relation to serum IL-18 (ELISA) concentration in 144 otherwise healthy men aged 51.9+/-12.5 years. RESULTS: In contrast to previous observations in women, circulating IL-18 was not significantly associated with BMI (r=0.12, p=0.1) or WHR (r=0.08, p=0.3). IL-18 was also not associated with absolute or percent fat mass (bioelectric impedance, p>0.20) but, interestingly, it was significantly linked to fat-free mass (p=0.03). Serum IL-18 increased with each quartile of fat-free mass, corresponding to values of < or = 64.2; >64.2 to < or = 71.6; >71.6 to < or = 80.9; and > or = 80.9 kg (ANOVA, p<0.0001). IL-18 was more closely associated with postload glucose during an OGTT (p=0.04) rather than with fasting glucose (p=0.1). HbA1c (p=0.03), HDL-cholesterol (p=0.04) and serum triglycerides (p=0.03) and parameters of systemic inflammation (C-reactive protein, p=0.02) were also significantly associated with circulating IL-18. Insulin sensitivity (minimal model analysis) was linked to circulating IL-18 (p=0.01). In a multiple linear regression analysis this relationship remained significant after controlling for BMI, age and glucose tolerance status. In another model, both fat-free mass and insulin sensitivity contributed to 10% of IL-18 variance. CONCLUSIONS/ INTERPRETATION: Fat mass does not seem to influence circulating IL-18, as initially proposed. In contrast, the fat-free mass compartment (a well-known confounder in the evaluation of insulin sensitivity) may significantly contribute to the relationship between IL-18 and insulin action.
Authors: Katherine Esposito; Francesco Nappo; Francesco Giugliano; Carmen Di Palo; Myriam Ciotola; Michelangela Barbieri; Giuseppe Paolisso; Dario Giugliano Journal: Diabetes Care Date: 2003-05 Impact factor: 19.112
Authors: J M Fernandez-Real; M Vayreda; C Richart; C Gutierrez; M Broch; J Vendrell; W Ricart Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Katherine Esposito; Francesco Nappo; Francesco Giugliano; Carmen Di Palo; Myriam Ciotola; Michelangela Barbieri; Giuseppe Paolisso; Dario Giugliano Journal: Am J Clin Nutr Date: 2003-12 Impact factor: 7.045
Authors: Héctor F Escobar-Morreale; José I Botella-Carretero; Gemma Villuendas; José Sancho; José L San Millán Journal: J Clin Endocrinol Metab Date: 2004-02 Impact factor: 5.958
Authors: Elizabeth A McKie; Juliet L Reid; Prafull C Mistry; Stephen L DeWall; Lee Abberley; Philip D Ambery; Blas Gil-Extremera Journal: PLoS One Date: 2016-03-01 Impact factor: 3.240